ストックスクリーナーアプリを入手
0.4397
3.29%
0.014
アフターアワーズ：
.44
0.0003
+0.07%
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech (MBRX) Awaits Canadian Patent for Annamycin In - GuruFocus
Moleculin Biotech Secures Canadian Patent for Annamycin - TipRanks
Moleculin receives Canadian patent allowance for cancer drug Annamycin - Investing.com
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin - GlobeNewswire
First Non-Cardiotoxic Anthracycline: Moleculin's Annamycin Gains Canadian Patent Protection Until 2040 - Stock Titan
Certain Options of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2025. - MarketScreener
Can Moleculin Biotech Inc. grow without dilutionJuly 2025 Recap & Advanced Swing Trade Entry Alerts - خودرو بانک
Moleculin Biotech (MBRX) Files to Sell 64.86 Million Common Shar - GuruFocus
Moleculin Biotech files prospectus for resale of common stockSEC Filing - MarketScreener
FOMO Trade: Will Moleculin Biotech Inc benefit from geopolitical trendsJuly 2025 Opening Moves & Technical Analysis for Trade Confirmation - خودرو بانک
Death Cross: Why is Moleculin Biotech Inc stock going up2025 Earnings Impact & Free Community Consensus Stock Picks - خودرو بانک
Aug PostEarnings: Can Moleculin Biotech Inc. stock outperform in a bear market2025 Retail Activity & Step-by-Step Trade Execution Guides - خودرو بانک
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Risk Off: Why is Moleculin Biotech Inc stock going up2025 Price Targets & Growth Focused Investment Plans - خودرو بانک
Published on: 2025-09-17 13:31:31 - خودرو بانک
Day Trade: Is CDRPRC a potential multi baggerTrade Exit Report & Fast Moving Market Watchlists - خودرو بانک
Aug Setups: Is Moleculin Biotech Inc likely to announce a buyback2025 Bull vs Bear & Daily Stock Momentum Reports - خودرو بانک
Treasury Yields: What are Moleculin Biotech Incs earnings expectations2025 Market Trends & High Win Rate Trade Alerts - خودرو بانک
Volume Report: Is Moleculin Biotech Inc forming higher highs and higher lowsJuly 2025 Price Swings & Daily Price Action Insights - خودرو بانک
Surprises Report: Can Moleculin Biotech Inc deliver consistent dividends2025 Big Picture & Trade Opportunity Analysis - خودرو بانک
Is Moleculin Biotech Inc. stock undervalued right nowJobs Report & Weekly High Return Opportunities - خودرو بانک
H.C. Wainwright reiterates Buy rating on Moleculin Biotech stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Moleculin Biotech stock - Investing.com
Moleculin Biotech accelerates recruitment in Phase 3 MIRACLE trial - Yahoo Finance
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial - GlobeNewswire
Moleculin Biotech Expands Global Phase 2B/3 Trial - TipRanks
Moleculin Biotech Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia - MarketScreener
Moleculin expands AML trial sites globally, targets 45 patients by Q4 - Investing.com
Moleculin Biotech, Inc. Expands Global Recruitment for MIRACLE Trial in Europe and the US, Aiming for 45 Patients by Q4 2025 - Quiver Quantitative
Global Expansion: Moleculin's MIRACLE Leukemia Trial Reaches 13 Patients, Targeting 45 for Key Data Analysis - Stock Titan
Moleculin Biotech Begins Phase 2B/3 MIRACLE Trial Enrollment - TipRanks
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia - GlobeNewswire
Moleculin Biotech Releases New Corporate Presentation - TipRanks
Moleculin enrolls first EU patients in pivotal AML cancer trial By Investing.com - Investing.com South Africa
Will Moleculin Biotech Inc. Sustain Its Chart BreakoutJuly 2025 Drop Watch & Smart Investment Allocation Tips - beatles.ru
Moleculin enrolls first EU patients in pivotal AML cancer trial - Investing.com
Moleculin doses first EU patient in phase 3 pivotal MIRACLE trial for treatment of Acute Myeloid Leukemia - MarketScreener
First EU Patients Enrolled: Moleculin's Phase 3 MIRACLE Trial Targets Hard-to-Treat Leukemia - Stock Titan
Moleculin Biotech Inc. Shows Support at Fibonacci LevelWeekly Risk Summary & Accurate Intraday Trade Tips - beatles.ru
Is Moleculin Biotech Inc. stock a smart retirement pickQuarterly Risk Review & Capital Efficient Trading Techniques - 뉴스영
Moleculin Biotech Completes Promising Annamycin Trial - MSN
Is Moleculin Biotech Inc. in a consolidation phaseShare Buyback & Daily Entry Point Alerts - خودرو بانک
Is Moleculin Biotech Inc. stock a buy or sellPortfolio Value Report & AI Powered Market Entry Strategies - خودرو بانک
What’s the outlook for Moleculin Biotech Inc.’s sectorJuly 2025 Trends & Weekly Top Performers Watchlists - خودرو بانک
Does Moleculin Biotech Inc. align with a passive investing strategyCEO Change & Smart Allocation Stock Tips - خودرو بانک
Backtesting results for Moleculin Biotech Inc. trading strategies2025 Investor Takeaways & Expert Verified Movement Alerts - Newser
Can Moleculin Biotech Inc. expand into new marketsEarnings Beat & Free Daily Entry Point Trade Alerts - خودرو بانک
Moleculin Biotech Inc. stock trend forecastQuarterly Trade Report & Risk Adjusted Buy/Sell Alerts - Newser
Custom watchlist performance reports with Moleculin Biotech Inc.Market Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
Long term hold vs stop loss in Moleculin Biotech Inc.Weekly Trend Summary & Low Risk High Win Rate Stock Picks - Newser
Volume spikes in Moleculin Biotech Inc. stock – what they meanJuly 2025 Trends & AI Powered Trade Plan Recommendations - Newser
Why Moleculin Biotech Inc. is moving todayPortfolio Value Report & Low Drawdown Trading Strategies - Newser
Using Bollinger Bands to evaluate Moleculin Biotech Inc.July 2025 Institutional & Real-Time Chart Pattern Alerts - Newser
2.43%
大文字化:
|
ボリューム (24 時間):